Simpler Grants.gov #RFA-CA-27-005

NCI Solicits Research Applications for Novel Glioblastoma Therapies

This opportunity from the National Cancer Institute (NCI) seeks research applications for developing and testing novel therapies for adult glioblastoma (GBM). - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Scope of Work: - Establish a collaborative network (Glioblastoma Therapeutics Network, GTN) to advance therapeutic agents from late pre-clinical development through IND studies and pilot clinical trials - Focus on novel agents that can cross the blood brain barrier - Repurposing agents approved for other indications for GBM treatment - Products/Services Requested: - Research and clinical trial services for novel and repurposed therapeutic agents - No specific products, part numbers, or OEMs named; solicitation is for research proposals - Unique Requirements: - Applicants must have clinical trial capability - Only U.S.-based organizations and components are eligible - Foreign entities are excluded - Estimated Funding: - Total funding available: $4,400,000 - Minimum award: $700,000 - Expected number of awards: 4

Description

The National Cancer Institute (NCI) is soliciting applications for research on novel therapies for adult glioblastoma (GBM) through this Notice of Funding Opportunity (NOFO). The goal is to improve treatment by developing novel effective agents that can cross the blood brain barrier and testing them clinically. A collaborative GBM Therapeutics Network (GTN) will be established to drive therapeutic agents from pre-clinical development through early clinical studies. The scope includes late pre-clinical through early (Phase 0/1) clinical studies, focusing on novel agents or repurposed agents for GBM treatment.

View original listing